Which has better valuation and earnings, ILMN or QGEN?

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 6.70 $850M $5.36 35.98 Qiagen $2.09B 4.21 $424.88M $1.95 21.87

Is ILMN or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% Qiagen 19.49% 14.24% 8.23%

Does the media favor ILMN or QGEN?

In the previous week, Qiagen had 2 more articles in the media than Illumina. MarketBeat recorded 25 mentions for Qiagen and 23 mentions for Illumina. Illumina's average media sentiment score of 0.83 beat Qiagen's score of 0.67 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 7 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ILMN or TMO?

In the previous week, Thermo Fisher Scientific had 19 more articles in the media than Illumina. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 23 mentions for Illumina. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Illumina's score of 0.83 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Thermo Fisher Scientific 30 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ILMN or A?

In the previous week, Illumina had 17 more articles in the media than Agilent Technologies. MarketBeat recorded 23 mentions for Illumina and 6 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.00 beat Illumina's score of 0.83 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ILMN or IQV?

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 6.70 $850M $5.36 35.98 IQVIA $16.31B 2.46 $1.36B $8.06 30.28

Is ILMN or IQV more profitable?

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% IQVIA 8.10% 30.25% 6.54%

Does the media prefer ILMN or IQV?

In the previous week, Illumina had 12 more articles in the media than IQVIA. MarketBeat recorded 23 mentions for Illumina and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.93 beat Illumina's score of 0.83 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, WAT or ILMN?

Illumina has higher revenue and earnings than Waters. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Waters $3.17B 12.87 $642.63M $4.01 103.48 Illumina $4.34B 6.70 $850M $5.36 35.98

Is WAT or ILMN more profitable?

Illumina has a net margin of 18.36% compared to Waters' net margin of 3.58%. Illumina's return on equity of 29.84% beat Waters' return on equity. Company Net Margins Return on Equity Return on Assets Waters 3.58% 11.27% 6.73% Illumina 18.36% 29.84% 12.17%

Does the media refer more to WAT or ILMN?

In the previous week, Waters had 6 more articles in the media than Illumina. MarketBeat recorded 29 mentions for Waters and 23 mentions for Illumina. Waters' average media sentiment score of 0.94 beat Illumina's score of 0.83 indicating that Waters is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Waters 16 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Illumina (ILMN) Competitors

$192.84 +1.05 (+0.55%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$195.90 +3.06 (+1.59%)

As of 08/11/2026 07:35 PM Eastern

Compare

ILMN vs. QGEN, TMO, A, IQV, and WAT

Should you buy Illumina stock or one of its competitors? Illumina's main competitors and comparable companies include Qiagen (QGEN), Thermo Fisher Scientific (TMO), Agilent Technologies (A), IQVIA (IQV), and Waters (WAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Illumina compare to Qiagen?

Illumina (NASDAQ:ILMN) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Illumina currently has a consensus target price of $188.40, indicating a potential downside of 2.30%. Qiagen has a consensus target price of $43.93, indicating a potential upside of 2.98%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	6.70	$850M	$5.36	35.98
Qiagen	$2.09B	4.21	$424.88M	$1.95	21.87

Illumina has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, Qiagen had 2 more articles in the media than Illumina. MarketBeat recorded 25 mentions for Qiagen and 23 mentions for Illumina. Illumina's average media sentiment score of 0.83 beat Qiagen's score of 0.67 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	7 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Qiagen	19.49%	14.24%	8.23%

89.4% of Illumina shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Illumina beats Qiagen on 12 of the 16 factors compared between the two stocks.

How does Illumina compare to Thermo Fisher Scientific?

Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

89.4% of Illumina shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Thermo Fisher Scientific had 19 more articles in the media than Illumina. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 23 mentions for Illumina. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Illumina's score of 0.83 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	30 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Illumina has a net margin of 18.36% compared to Thermo Fisher Scientific's net margin of 15.04%. Illumina's return on equity of 29.84% beat Thermo Fisher Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

Illumina has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	6.70	$850M	$5.36	35.98
Thermo Fisher Scientific	$44.56B	5.01	$6.70B	$18.59	32.50

Illumina currently has a consensus target price of $188.40, indicating a potential downside of 2.30%. Thermo Fisher Scientific has a consensus target price of $619.41, indicating a potential upside of 2.52%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Illumina and Thermo Fisher Scientific tied by winning 8 of the 16 factors compared between the two stocks.

How does Illumina compare to Agilent Technologies?

Illumina (NASDAQ:ILMN) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Agilent Technologies has a net margin of 19.55% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Agilent Technologies	19.55%	24.33%	12.99%

Agilent Technologies has higher revenue and earnings than Illumina. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	6.70	$850M	$5.36	35.98
Agilent Technologies	$6.95B	6.07	$1.30B	$4.98	29.98

Illumina has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

89.4% of Illumina shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Illumina presently has a consensus target price of $188.40, suggesting a potential downside of 2.30%. Agilent Technologies has a consensus target price of $159.35, suggesting a potential upside of 6.73%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Illumina had 17 more articles in the media than Agilent Technologies. MarketBeat recorded 23 mentions for Illumina and 6 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.00 beat Illumina's score of 0.83 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Illumina on 9 of the 17 factors compared between the two stocks.

How does Illumina compare to IQVIA?

Illumina (NASDAQ:ILMN) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Illumina currently has a consensus target price of $188.40, suggesting a potential downside of 2.30%. IQVIA has a consensus target price of $241.88, suggesting a potential downside of 0.90%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

89.4% of Illumina shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	6.70	$850M	$5.36	35.98
IQVIA	$16.31B	2.46	$1.36B	$8.06	30.28

Illumina has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

In the previous week, Illumina had 12 more articles in the media than IQVIA. MarketBeat recorded 23 mentions for Illumina and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.93 beat Illumina's score of 0.83 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
IQVIA	8.10%	30.25%	6.54%

Summary

IQVIA beats Illumina on 9 of the 16 factors compared between the two stocks.

How does Illumina compare to Waters?

Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Waters had 6 more articles in the media than Illumina. MarketBeat recorded 29 mentions for Waters and 23 mentions for Illumina. Waters' average media sentiment score of 0.94 beat Illumina's score of 0.83 indicating that Waters is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Waters	16 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Waters has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Illumina has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Illumina has a net margin of 18.36% compared to Waters' net margin of 3.58%. Illumina's return on equity of 29.84% beat Waters' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Waters	3.58%	11.27%	6.73%
Illumina	18.36%	29.84%	12.17%

Waters currently has a consensus target price of $420.35, indicating a potential upside of 1.30%. Illumina has a consensus target price of $188.40, indicating a potential downside of 2.30%. Given Waters' stronger consensus rating and higher possible upside, analysts plainly believe Waters is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waters	0 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.75
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Illumina has higher revenue and earnings than Waters. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waters	$3.17B	12.87	$642.63M	$4.01	103.48
Illumina	$4.34B	6.70	$850M	$5.36	35.98

94.0% of Waters shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 0.3% of Waters shares are held by insiders. Comparatively, 2.9% of Illumina shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Waters beats Illumina on 9 of the 17 factors compared between the two stocks.

Get Illumina News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ILMN vs. The Competition

Export

Metric	Illumina	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.96B	$9.72B	$7.09B	$12.96B
Dividend Yield	N/A	1.46%	2.57%	10.34%
P/E Ratio	35.98	63.40	268.42	25.05
Price / Sales	6.70	107.96	593.33	87.68
Price / Cash	28.56	26.22	72.26	50.42
Price / Book	10.26	38.70	13.21	6.18
Net Income	$850M	$56.66B	$3.44B	$347.05M
7 Day Performance	-5.01%	4.77%	2.27%	0.99%
1 Month Performance	1.39%	2.15%	-0.23%	-0.64%
1 Year Performance	103.46%	26.40%	76.15%	22.27%

Illumina Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ILMN Illumina	3.2021 of 5 stars	$192.84 +0.5%	$188.40 -2.3%	+103.5%	$28.96B	$4.34B	35.98	8,650
QGEN Qiagen	3.8078 of 5 stars	$42.34 +0.0%	$43.34 +2.4%	-15.6%	$8.72B	$2.09B	22.11	5,654	Earnings Report Analyst Forecast Options Volume
TMO Thermo Fisher Scientific	4.5711 of 5 stars	$564.48 -1.7%	$617.14 +9.3%	+30.6%	$212.25B	$44.56B	30.36	125,000	Trending News Insider Trade
A Agilent Technologies	4.636 of 5 stars	$139.33 -0.3%	$159.35 +14.4%	+30.7%	$39.48B	$6.95B	27.98	18,100
IQV IQVIA	4.0365 of 5 stars	$228.18 -2.2%	$241.88 +6.0%	+35.5%	$38.41B	$16.31B	28.31	93,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ILMN) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Competitors